19:33:13 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

2026-04-29 16:00 ET - News Release

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

PR Newswire

GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:


 Conference call details:



 Date:                    
 May 6, 2026



 Time:                    
 8:30 a.m. ET



 URL to register phone:                Register Here



 Dial-in number:            (888) 880-3330 (U.S.) or


                                          (+1) (646) 357-8766
                                              (International)



 Webcast:                              ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
  Replay details:



 Date:             Available starting at 11:30 a.m. ET, May 6, 2026, until 11:59 p.m.
                     ET, May 13, 2026


  Dial-in number: 
 (800) 770-2030 (U.S.) or


                                        
          (+1) (609) 800-9909 (International)


  Passcode:       
 1309751#


  Webcast:        
 
            ir.novavax.com/events, until June 6, 2026

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Jim Kelly
844-668-2829
ir@novavax.com

Media
Yvonne Sprow
844-264-8571
media@novavax.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-first-quarter-2026-financial-results-on-may-6-2026-302757475.html

SOURCE Novavax, Inc.

© 2026 Canjex Publishing Ltd. All rights reserved.